Evidence map›Paper›PMID 39841800›Full record

ArticlePLoS pathogens2025

The R203M and D377Y mutations of the nucleocapsid protein promote SARS-CoV-2 infectivity by impairing RIG-I-mediated antiviral signaling.

Yongkui Li, Moran Li, Heng Xiao, Feng Liao, Miaomiao Shen, Weiwei Ge, Junxian Ou, Yuqing Liu, Lumiao Chen, Yue Zhao and 9 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Evolution of a fuzzy ribonucleoprotein complex in viral assembly.bioRxiv : the preprint server for biology · 2025
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yongkui LiState Key Laboratory of Respiratory Disease, School of Basic Medical Science, Guangzhou Medical University, Guangzhou, China.
Moran LiKey Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou, China.
Heng XiaoKey Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou, China.
Feng LiaoLaboratory Animal Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Miaomiao ShenGuangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Weiwei GeKey Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou, China.
Junxian OuKey Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou, China.
Yuqing LiuKey Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou, China.
Lumiao ChenThe First Affiliated Hospital of Jinan University, Guangzhou, China.
Yue ZhaoKey Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou, China.
Pin WanKey Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou, China.
Jinbiao LiuKey Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou, China.
Jun ChenKey Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou, China.
Xianwu LanThe First Affiliated Hospital of Jinan University, Guangzhou, China.
Shaorong WuThe First Affiliated Hospital of Jinan University, Guangzhou, China.
Qiang DingSchool of Medicine, Tsinghua University, Beijing, China.
Geng LiLaboratory Animal Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Qiwei ZhangKey Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou, China.
Pan PanState Key Laboratory of Respiratory Disease, School of Basic Medical Science, Guangzhou Medical University, Guangzhou, China.ORCID 0000-0002-3296-8695

Funding

Guangdong Basic and Applied Basic Research FoundationNational Natural Science Foundation of ChinaOpen Research Fund Program of Guangdong Provincial Key Laboratory of VirologyOpen Research Fund Program of the State Key Laboratory of Virology of ChinaR&D Program of Guangzhou Laboratory
6 · The paper itself

Abstract

The viral protein mutations can modify virus-host interactions during virus evolution, and thus alter the extent of infection or pathogenicity. Studies indicate that nucleocapsid (N) protein of SARS-CoV-2 participates in viral genome assembly, intracellular signal regulation and immune interference. However, its biological function in viral evolution is not well understood. SARS-CoV-2 N protein mutations were analyzed in Delta, Omicron, and original strains. Two mutations with a methionine (M) residue at site 203 and a tyrosine (Y) residue at site 377 of the N protein were found in Delta strain but not in Omicron and original strains, and promoted SARS-CoV-2 infection therein. Those mutations, R203M and D377Y, enhanced the inhibitory impact of N protein on the impairment of RIG-I-mediated antiviral signaling, such as IRF3 phosphorylation and IFN-β activation. The viral RNA-binding activity of N protein was promoted by these mutations, effectively attenuating the recognition and interaction of RIG-I with viral RNA compared to the original or other variants. The R203M/D377Y mutations thus enhanced the suppressive activity of the N protein on RIG-I-mediated interferon induction both in vitro and in vivo, which in turn promoted viral replication. This study helps to understand the variability of SARS-CoV-2 in regulating host immunity.

Indexed as

Coronavirus Nucleocapsid ProteinsCOVID-19DEAD Box Protein 58Nucleocapsid ProteinsSARS-CoV-2AnimalsChlorocebus aethiopsHEK293 CellsHumansInterferon Regulatory Factor-3MiceMutationPhosphoproteinsReceptors, ImmunologicSignal TransductionVero CellsCoronavirus Nucleocapsid ProteinsDEAD Box Protein 58Interferon Regulatory Factor-3IRF3 protein, humannucleocapsid phosphoprotein, SARS-CoV-2Nucleocapsid ProteinsPhosphoproteinsReceptors, ImmunologicRIGI protein, human

Identifiers

PMID39841800
PMCPMC11771877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.